Teriflunomide Accord
teriflunomide
Table of contents
Overview
Teriflunomide Accord is a medicine used to treat patients from the age of 10 years with multiple sclerosis (MS), a disease in which inflammation attacks the protective covering (sheath) around nerves and damages the nerves themselves.
Teriflunomide Accord is used in the type of MS known as relapsing-remitting MS, when the patient has flare-ups of symptoms (relapses) followed by periods of recovery (remissions).
Teriflunomide Accord is a ‘generic medicine’. This means that Teriflunomide Accord contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Aubagio. For more information on generic medicines, see the question-and-answer document here.
Teriflunomide Accord contains the active substance teriflunomide.
-
List item
Teriflunomide Accord : EPAR - Medicine Overview (PDF/144.61 KB)
First published: 14/11/2022
EMA/CHMP/857461/2022 -
-
List item
Teriflunomide Accord : EPAR - Risk management plan summary (PDF/106.9 KB)
First published: 14/11/2022
Authorisation details
Product details | |
---|---|
Name |
Teriflunomide Accord
|
Agency product number |
EMEA/H/C/005960
|
Active substance |
Teriflunomide
|
International non-proprietary name (INN) or common name |
teriflunomide
|
Therapeutic area (MeSH) |
Multiple Sclerosis, Relapsing-Remitting
|
Anatomical therapeutic chemical (ATC) code |
L04AA31
|
Generic |
This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines. |
Publication details | |
---|---|
Marketing-authorisation holder |
Accord Healthcare S.L.U.
|
Date of issue of marketing authorisation valid throughout the European Union |
09/11/2022
|
Contact address |
Accord Healthcare S.L.U. |
Product information
Teriflunomide Accord - EMEA/H/C/005960 -
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Immunosuppressants
-
Selective immunosuppressants
Therapeutic indication
Teriflunomide Accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (MS) (please refer to section 5.1 for important information on the population for which efficacy has been established).